NEW YORK (Reuters) - Wyeth on Wednesday said insurers have been more reluctant than expected to reimburse patients for its recently approved Pristiq depression drug, but the company stuck to its ...

NEW YORK, Oct 15 (Reuters) - Wyeth has decided against pursuing European approval for its depression treatment for now after consulting with regulators, the company said on Wednesday. The drug maker ...

Desvenlafaxine, the major active metabolite of venlafaxine (Effexor XR, also from Wyeth), is a potent and selective SNRI. The increase in the effects of these neurotransmitters in the central nervous ...

Report > Russia's Veropharm posted first-quarter profits of 494.3 million roubles, or $14.83 million, a 46% increase, fueled by rising demand for prescription drugs. Report > Cholesterol-fighting ...

After my suicide attempt and subsequent psychiatric hospitalization in 2014, all my medication was changed. I was started on a different antidepressant (Pristiq, 100 mg.) and a different antipsychotic ...